28 Oct 2018

Professor Mike Barnes On The Urgent Need For Medical Education In Cannabis.

See 'Cannabis Advocates Really Need To Stop Accusing Doctors of Being Bribed By Pharmaceutical Companies.' The urgent need now is physician education. Doctors just don’t know about the endocannabinoid system. They have never been taught it and thus don’t understand it and certainly don’t appreciate the benefit of medicinal cannabis. Only education will slowly change entrenched positions. The launch of the Academy of Medical Cannabis next week will go some way to help - see the website. I hope that the Medical...

28 Oct 2018

Cannabis Advocates Really Need To Stop Accusing Doctors of Being Bribed By Pharmaceutical Companies.

There may well be some doctors who are corrupt and there are still, despite much improvement, serious questions over the relationship between pharma companies and doctors but the idea that every member of the Faculty of Pain Medicine who signed that letter to the Times is taking bribes is ridiculous. The real reason is ignorance and that's not an attack on doctors, it's a reason. They have been subject to the same relentless torrent of reefer madness propaganda from government and...

26 Oct 2018

British Doctors Don’t Understand Cannabinoid Medicine. They’ve Been Denied Education In The Basic Science.

Today's letter to the Times from a group of pain medicine consultants (reproduced below) is is an astonishing display of evidence-free ignorance from a profession that needs to challenge its own prejudice. To compare the addiction potential of cannabis with opioids is ridiculous and demonstrates just how detached from the science and evidence are those making this claim. Doctors will understandably feel challenged by a medicine that upturns many of their conventional habits. They have been prevented from understanding the science of...

18 Oct 2018

The MHRA On CBD/Hemp Products And Its Relationship With Trade Associations

This is an email from the MHRA to a CBD/Hemp supplier which name is redacted. It clearly sets out the MHRA's position regarding the Cannabis Trades Association, its 'Cannabis Products Directive' proposal and how anyone is able to obtain advice from the MHRA without having to join any trade association. It also explains how medical claims may only be made about a CBD product if it has the required licence known as a marketing authorisation. This is authoritative guidance from the...

12 Oct 2018

Will I Be Able To Get Cannabis Prescribed On The NHS?

With the publication of new regulations yesterday, it is now clear how cannabis will be available on the NHS starting on 1st November 2018. Only consultants will be able to prescribe cannabis and it will be entirely up to each consultant to make a decision about individual patients. The definition of cannabis-derived medicinal products is sufficently wide that both oils and herbal cannabis manufactured to GMP (Good Manufacturing Practice) standards will be available. There is very little explanation included in the regulations...

13 Sep 2018

CLEAR Advises Department of Health and MHRA on Definition of Cannabis-Derived Medicinal Products.

Last week, CLEAR was invited to participate in a teleconference with representatives of the Department of Health and Social Care (DHSC) and the Medicines and Healthcare products Regulatory Agency (MHRA). This followed our written submissions made over the last few weeks. The teleconference included two representatives from each party. The DHSC was represented by the Medicines Pharmacy and Industry section. The MHRA was represented by the Licensing Division. CLEAR has now submitted a summary of all the advice offered which is reproduced...

26 Jul 2018

The Definition Of A Cannabis-Derived Medicinal Product Must Include Standardised Herbal Cannabis Or Sajid Javid’s Reform Will Fail.

Bedrocan, the Netherlands government's official producer, grows cannabis in which the cannabinoid and terpene content is standardised and consistent. It does this by very careful cultivation techniques which include clonal propagation, continuous analysis and gamma irradiation to eliminate contamination with potentially harmful microbes. Its production facility is Good Manufacturing Practice (GMP) certified. With the exception of Sativex, which NICE has declared as not cost effective, the Bedrocan range offers the only medicinal cannabis products which could be readily available in the...

05 Jul 2018

An ‘Expert Panel’ On Medicinal Cannabis Without A Single Expert On It?

To be fair, the members of the expert panel are hardly a surprise. It's the medical establishment writ large. The chairman, Dr John McBride, was, according to Charlotte Caldwell, "instrumental" in stopping Billy's medicine being prescribed, despite the original prescription coming from a consultant neurologist specialising in paediatric epilepsy. A government which has denied any medicinal value in cannabis for nearly 50 years needs 'cover' for its long...

04 Jul 2018

Dame Sally’s Caution On “Grown Cannabis” Does Not Bode Well For Access To Herbal Cannabis As Medicine.

Great news all round! Professor Dame Sally Davies has, within a matter of days concluded that cannabis does have medicinal value and needs to be removed from schedule 1. No surprise really as the evidence is, as Dame Sally says, "overwhelming". The simple fact is that our government has been deliberately ignoring it for years. However, reading Dame Sally's report yesterday I was immediately struck by her use of the term "grown cannabis" in a disparaging sense. I’m tempted to ask...

30 Jun 2018

A Quick, Easy Guide to The New UK Arrangements For Access To Cannabis As Medicine.

There's already an awful lot of misunderstanding over the arrangements just introduced for medicinal cannabis and there's no need for it because, to be fair, the government has been very clear. There is an interim procedure which will be very, very difficult for most to achieve. You must have very strong support from your doctor and they, together with your local NHS Trust, must be prepared to put in a lot of work, form-filling and pay some substantial licensing fees. It's...